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We read with great interest the study in CMI by
Rodriguez et al. [1] concerning the impact of early
central venous catheter (CVC) removal on out-
come in patients with candidaemia in Barcelona,
Spain. In this study, the most predictive marker of
in-hospital mortality was the severity of illness
according to APACHE II score. Interestingly,
early CVC removal (i.e., CVC removal on day 0
or 1 following the diagnosis of candidaemia) was
not associated with signiﬁcantly decreased odds
of in-hospital mortality. In addition, the time to
death among cases with early CVC removal, as
compared to delayed CVC removal, did not differ
signiﬁcantly according to Kaplan–Meier survival
analysis in the overall patient population and in
subgroups of patients (critically-ill, surgical and
neoplastic patients). In a recent CMI Editorial,
Pasqualotto and Severo [2] argued that the main
question to be answered might not be whether
early CVC removal can decrease mortality, but
rather, whether CVC removal actually has any
impact on overall mortality in candidaemic
patients. In a retrospective study examining the
impact of CVC removal in 93 adult patients (12
neutropenic) with candidaemia, Pasqualotto and
Severo [2] reported that CVCs were removed in
69.9% of patients after a median time of 4.0 days
(range 1–50 days), and 17.2% of patients were
shown to have CVC-related candidaemia. The
overall in-hospital mortality rate was 62.4%. In
this study, multivariate analysis revealed that
death was associated with an APACHE II
score >15 and intensive care unit admission at
the onset of candidaemia, but not with removal of
the CVC.
In a previous retrospective study [3], we
reported data from a survey of nosocomial can-
didaemia among non-neutropenic patients in an
Italian tertiary hospital. Among 284 evaluable
patients with candidaemia, 30-day crude mortal-
ity was 41%, which is consistent with previous
reports [1,4]. In this series, 138 (48.6%) patients
received adequate antifungal therapy 4 ± 3 days
after the onset of fungaemia. Of 201 patients with
temporary non-tunnelled CVCs who were assess-
able for catheter removal, 142 (70.6%) underwent
central line removal 5 ± 2 days after the onset of
candidaemia. Ninety-three (66.5%) of these 142
patients had CVC-related fungaemia. According
to logistic regression analysis, factors that inde-
pendently predicted death in the 284 evaluable
patients were an age ‡60 years, hospitalisation in
an intensive care unit, inadequate antifungal
therapy, and rapidly fatal underlying disease
according to the modiﬁed McCabe scale. Among
the 201 patients evaluable for CVC status, reten-
tion of the CVC was an additional factor that was
associated independently with higher mortality,
whereas having a rapidly fatal underlying disease
was no longer a risk-factor. In both analyses,
candidaemia caused by Candida albicans only,
excluding non-albicans Candida spp. or polymicro-
bial episodes, was a condition associated with a
higher probability of death, as also reported
elsewhere [5]. The latter ﬁnding is consistent with
the high proportion of candidaemia caused by
Candida parapsilosis, which is typically associated
with low mortality rates [4].
Candidaemia remains an important problem
worldwide, and no signiﬁcant decreases in crude
and attributable mortality rates associated with
this disease have been reported to date. Antifun-
gal treatment of candidaemia is often inadequate
because of an erroneous choice of drug, drug dose
or duration of treatment, an absence of any
treatment, or a delay in administration of anti-
fungal therapy [4]. Morrell et al. [6] demonstrated
that a delay of >12 h in initial empirical treatment
of Candida bloodstream infection following the
ﬁrst positive blood sample is associated with a
greater risk of hospital mortality. Similarly, delays
in the initiation of adequate therapy of >24 h and
>48 h have been found to be associated indepen-
dently with mortality in candidaemic patients
[7,8]. These ﬁndings underscore the importance of
diagnostic testing and empirical or ‘very early’
antifungal treatment strategies in this setting.
Although the most recent guidelines from the
Infectious Diseases Society of America for the
treatment of candidaemia recommend that initial
non-medical management of candidaemia should
include removal of all existing CVCs, at least for
non-neutropenic patients [9], the optimal timing
of this procedure remains a controversial issue.
Rodriguez et al. [1] demonstrated that early CVC
removal does not improve the outcome of adult
patients with candidaemia, even in those with
CVC-related candidaemia. Since removal of cath-
eters, as well as antifungal treatment, has been
found previously to be critical in preventing both
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early and late mortality in this patient population
[10], it can be argued that CVC removal might be
delayed without reducing the survival of these
patients. Similarly, catheter removal was delayed
in our series following the diagnosis of candida-
emia, and the procedure was found to be associ-
ated independently with a decrease in mortality.
In contrast, Pasqualotto and Severo [2] showed
that delayed CVC removal had no impact on
overall mortality following adjustment for con-
founding variables such as the severity of illness.
However, some of their patients were neutrope-
nic, and the majority did not have CVC-related
candidaemia [2].
In conclusion, treatment of candidaemia must
include timely adoption of antifungal therapy. We
agree that a properly designed randomised trial is
needed to deﬁne the subgroups of patients that
would beneﬁt from CVC removal and the best
timing of this intervention. However, at present,
we believe that removal of CVCs remains a
mandatory procedure in the management of
documented or suspected catheter-related candi-
daemia episodes in non-neutropenic patients.
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